{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:04:19Z","timestamp":1768277059601,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.taap.2022.116213","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T12:10:02Z","timestamp":1661775002000},"page":"116213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors"],"prefix":"10.1016","volume":"453","author":[{"given":"Sai Charitha","family":"Mullaguri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sravani","family":"Akula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vigneshwar Reddy","family":"Ashireddygari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partha Sarathi","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.L.S. Prasad","family":"Burra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravalika","family":"Silveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vyshnavika","family":"Mupparapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghana","family":"Korikani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nageswara Rao","family":"Amanchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janakiraman","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama Krishna","family":"Kancha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10026","key":"10.1016\/j.taap.2022.116213_bb0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Biomarkers France contributors, routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.taap.2022.116213_bb0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.taap.2022.116213_bb0015","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"issue":"269","key":"10.1016\/j.taap.2022.116213_bb0020","doi-asserted-by":"crossref","first-page":"pI1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"6","key":"10.1016\/j.taap.2022.116213_bb0025","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molcel.2005.10.022","article-title":"Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization","volume":"20","author":"Garnett","year":"2005","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.taap.2022.116213_bb0030","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1038\/s41467-019-13161-x","article-title":"Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers","volume":"10","author":"Gopal","year":"2019","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.taap.2022.116213_bb0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.taap.2022.116213_bb0040","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11523-019-00669-x","article-title":"Acquired BRAF G469A mutation as a resistance mechanism to first-line Osimertinib treatment in NSCLC cell lines harboring an EGFR exon 19 deletion","volume":"14","author":"La Monica","year":"2019","journal-title":"Target. Oncol."},{"issue":"11","key":"10.1016\/j.taap.2022.116213_bb0045","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/JTO.0000000000000344","article-title":"Clinical characteristics and course of 63 patients with BRAF mutant lung cancers","volume":"9","author":"Litvak","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.taap.2022.116213_bb0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7666","key":"10.1016\/j.taap.2022.116213_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature23297","article-title":"A Braf kinase-inactive mutant induces lung adenocarcinoma","volume":"548","author":"Nieto","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.taap.2022.116213_bb0060","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: Dabrafenib and Trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.taap.2022.116213_bb0065","article-title":"BRAF in lung cancers: analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations","volume":"2","author":"Sheikine","year":"2018","journal-title":"JCO Precis Oncol."},{"issue":"6","key":"10.1016\/j.taap.2022.116213_bb0070","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X22003581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X22003581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:59:12Z","timestamp":1758574752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X22003581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":14,"alternative-id":["S0041008X22003581"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2022.116213","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2022.116213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116213"}}